SCM
BPMC

Soleus Capital Management’s Blueprint Medicines BPMC Stock Holding History

Soleus Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,454
Closed -$1.9M – 67
2020
Q3 		$1.9M Buy
+20,454
New +$1.58M 1.01% 32
2020
Q1 		– Sell
-26,400
Closed -$2.11M – 51
2019
Q4 		$2.11M Buy
+26,400
New +$1.98M 2.04% 20

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Soleus Capital Management's BPMC Position: Q4 2020 in Review

Soleus Capital Management sold out of Blueprint Medicines (BPMC) in Q4 2020, closing a stake of 20,454 shares — an estimated $1.9M sold.

Soleus Capital Management first reported a position in BPMC in Q4 2019 and held it in 2 quarters. The position peaked at $2.11M in Q4 2019. 278 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

  • Soleus Capital Management reported no remaining Blueprint Medicines position as of Q4 2020 after selling out during the quarter.
  • Soleus Capital Management sold 20,454 Blueprint Medicines shares in Q4 2020, an estimated $1.9M.
  • Soleus Capital Management first reported a position in Blueprint Medicines in Q4 2019 and held it in 2 quarters.
  • Soleus Capital Management's Blueprint Medicines position peaked at $2.11M in Q4 2019.
  • 278 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on Soleus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.